Deals
Qiagen Weighs Stake Sale in $1 Billion Bioinformatics Arm
- Diagnostics group is working with an adviser to weigh options
- Business is likely to draw interest from private equity firms
This article is for subscribers only.
Qiagen NV is weighing the sale of a minority stake in its bioinformatics division, which could value that business at more than $1 billion, people familiar with the matter said.
The Dutch diagnostics firm is working with a financial adviser as it explores bringing in an investor, according to the people. Selling a stake in the unit, which provides software for analyzing biological data, could help fund further growth in this business, the people said.